^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HB0036

    i
    Other names: HB0036
    Associations

    News

    Trials
    Company:
    Zhejiang Huahai Pharma
    Drug class:
    PD-L1 inhibitor, TIGIT inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    HB0036
    almost2years
    A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=80, Not yet recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    HB0036